HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.

AbstractBACKGROUND:
Renal failure is the most important comorbidity in patients with heart transplantation, it is associated with increased mortality. The major cause of renal dysfunction is the toxic effects of calcineurin inhibitors (CNI). Sirolimus, a proliferation signal inhibitor, is an imunossupressant recently introduced in cardiac transplantation. Its nonnephrotoxic properties make it an attractive immunosuppressive agent for patients with renal dysfunction. In this study, we evaluated the improvement in renal function after switching the CNI to sirolimus among patients with new-onset kidney dysfunction after heart transplantation.
METHODS:
The study included orthotopic cardiac transplant (OHT) patients who required discontinuation of CNI due to worsening renal function (creatinine clearance < 50 mL/min). We excluded subjects who had another indication for initiation of sirolimus, that is, rejection, malignancy, or allograft vasculopathy. The patients were followed for 6 months. The creatinine clearance (CrCl) was estimated according to the Cockcroft-Gault equation using the baseline weight and the serum creatinine at the time of introduction of sirolimus and 6 months there after. Nine patients were included, 7 (78%) were males and the overall mean age was 60.1 +/- 12.3 years and time since transplantation 8.7 +/- 6.1 years. The allograft was beyond 1 year in all patients. There was a significant improvement in the serum creatinine (2.98 +/- 0.9 to 1.69 +/- 0.5 mg/dL, P = .01) and CrCl (24.9 +/- 6.5 to 45.7 +/- 17.2 mL/min, P = .005) at 6 months follow-up.
CONCLUSION:
The replacement of CNI by sirolimus for imunosuppressive therapy for patients with renal failure after OHT was associated with a significant improvement in renal function after 6 months.
AuthorsS M Ayub-Ferreira, M S Avila, F S Feitosa, G E C Souza, S Mangini, F G Marcondes-Braga, V S Issa, F Bacal, P R Chizzola, F D D Cruz, E A Bocchi
JournalTransplantation proceedings (Transplant Proc) Vol. 42 Issue 2 Pg. 542-4 (Mar 2010) ISSN: 1873-2623 [Electronic] United States
PMID20304188 (Publication Type: Journal Article)
CopyrightCopyright (c) 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Creatinine
  • Sirolimus
Topics
  • Aged
  • Calcineurin Inhibitors
  • Creatinine (metabolism)
  • Female
  • Follow-Up Studies
  • Heart Transplantation (adverse effects, immunology, physiology)
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Kidney Function Tests
  • Male
  • Middle Aged
  • Patient Selection
  • Renal Insufficiency (epidemiology, etiology, prevention & control)
  • Reoperation (statistics & numerical data)
  • Retrospective Studies
  • Sirolimus (adverse effects, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: